PPIs reduces the antiplatelt effects of clopidogrel: According to a 2007 survey, clopidogrel is the sixth most commonly.

Slides:

Advertisements

Similar presentations

Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines INTERACTION BETWEEN CLOPIDROGEL AND PROTON PUMP INHIBITORS Working.

Advertisements

J. Mehilli, A. Kastrati, K. Huber, S. Schulz, J. Pache, C.Markwardt, S. Kufner, F. Dotzer, K. Schlotterbeck, J. Dirschinger, A. Schömig. Abciximab in Patients.

1 Literature Review Peter R. McNally, DO, FACP, FACG University Colorado Denver School of Medicine Center for Human Simulation Aurora, Colorado

Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO Shaun G. Goodman,

Inhibitory Effects of Ticagrelor Compared to Clopidogrel on Platelet Function in Patients with Acute Coronary Syndromes The PLATO PLATELET Substudy Storey.

Hepatic generation of active metabolite Pharmacogenetics of Cardiovascular Antithrombotic Therapy CYP = cytochrome P450. GP = glycoprotein. MDR = multidrug.

CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.

Zontivity™ - vorapaxar

Antiplatelet therapy in CAD MINILECTURE. Objectives Indications for Antiplatelet Therapy in patients with CAD and ACS Antiplatelet Therapy in the role.

Clopidogrel in ACS: Overview Investigator, TIMI Study Group Associate Physician, Cardiovascular Division, BWH Assistant Professor of Medicine, Harvard.

ADP Receptors Bhatt DL et al. Nature Reviews Drug Discovery 2003; 2:15-28.

NEJM journal discussion Dr. J.A. Coetser Dr. J-M Nel 24 February 2011.

Point of Care Platelet Function Testing – Is There Still Value?

Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.

C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.

Introduction Clopidogrel is metabolized by P450 (CYP)-isoenzymes: CYP 3A4/5, 1A2, 2B6, 2C9, and 2C19 1 Wide response variability and nonresponsiveness.

S. Banai, M.D. Loading dose with Clopidogrel before PCI How high should we go? Shmuel Banai, MD Director, Interventional Cardiology Tel Aviv Medical Center.

Cardiovascular Outcomes and Mortality in Patients Using Clopidogrel With Proton Pump Inhibitors After Percutaneous Coronary Intervention or Acute Coronary.

Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.

Clopidogrel 75 mg per day orally should be added to aspirin in patients with STEMI regardless of whether they undergo reperfusion.

High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.

The Influence of Proton Pump Inhibitors on Clinical Outcomes After Successful Percutaneous Coronary Intervention Kishore J. Harjai, MD, FACC Chetan Shenoy,

ANTIPLATELET DRUGS.

Clinical Trial Results. org Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients with Diabetes Mellitus and Coronary Artery Disease:

Proton Pump Inhibitor (PPI) Studies

INTRODUCTION Dual antiplatelet therapy is a cornerstone of medical therapy for patients undergoing percutaneous coronary intervention (PCI) for coronary.

Hideki Shimomura, MD* 1 ; Seiji Hokimoto, MD* 2 ; Shuichi Oshima, MD* 3 ; Koichi Nakao, MD* 4 ; Yuji Miyao, MD* 5 ; Hisao Ogawa, MD* 2 ; for the Kumamoto.

Use of PPIs during Clopidogrel Therapy Andrew N. Schmelz, PharmD Post-Doctoral Teaching Fellow Dept of Pharmacy Practice Purdue University February 26,

B-1 Pravastatin-Aspirin Combination René Belder, M.D. Executive Director Clinical Design and Evaluation, Metabolics Pharmaceutical Research Institute Bristol-Myers.

The Risk of CV Events for Patients Treated with Clopidogrel or Prasugrel in Combination with a Proton Pump Inhibitor Results from the TRITON-TIMI 38 Trial.

Mechanism of Action of Aspirin Carlo Patrono, et al, N Engl J Med 2005;353:

Medical management after PCI Ma Hong 1 st affiliated hospital of Sun Yat-sen University.

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.

CHEMISTRY 4000 Problem Set #4: Ticlopidine (aka Ticlid ® ) Fall 2012 Dr. Susan Findlay.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Patients With Poor Responsiveness to Thienopyridine.

Adapted from Angiolillo DJ et al. Am J Cardiol. 2006;97: Individual Response Variability to Dual Antiplatelet Therapy in the Steady State Phase of.

Benadryl And Plavix Cheap Clopidogrel No Prescription clopidogrel prospect pret romania plavix generic for plavix suppliers clopidogrel lungenembolie clopidogrel.

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pharmacodynamic Effects of Switching From Prasugrel.

Cardiovascular and Gastrointestinal Outcomes in Clopidogrel Users on Proton Pump Inhibitors: Results of a Large Dutch Cohort Study 소화기 내과 R1 박지윤 Ofke S.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

New Anti-platelet Agents

_________________ Caitlin M. Gibson, PharmD, BCPS

PhenGene P2Y12 Test.

The American College of Cardiology Presented by Dr. Adnan Kastrati

Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.

Anne Masich, PharmD PGY1 Resident University of Maryland

Randomisation before planned PCI with DES (n=2500)

Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin The Randomized, Double-Blind OCLA(Omeprazole CLopidogrel Aspirin)

Francesco Franchi, MD, Fabiana Rollini, MD, Jose Rivas Rios, MD, Andrea Rivas, MD, Malhar Agarwal, MD, Megha Kureti, MD, Deepa Nagaraju, MD, Mustafa Wali,

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

The following slides are based on a report from presentations at an official Satellite Symposium during the Annual Scientific Sessions of the American.

These slides highlight a report on a Mini-Course and original contributions at the American College of Cardiology 53rd Annual Scientific Session in New.

Figure 4 Activation of clopidogrel via cytochrome P450

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Up to Date on Which NOAC for Which Patient

Tailoring Antiplatelet Therapy in PCI

NOACS: Emerging data in ACS/IHD

Section F: Clinical guidelines

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

Roberta Rossini et al. JCIN 2018;11:

Anti-Platelet Drugs Dr. A. Shyam Sundar. M.Pharm., Ph.D,

The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing

Effect of Additional Temporary Glycoprotein IIb-IIIa Receptor Inhibition on Troponin Release in Elective Percutaneous Coronary Interventions After Pretreatment.

Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.

Section C: Clinical trial update: Oral antiplatelet therapy

Dervin Ariansyah 1. Antiplatelet Therapy Aspirin Acetysalicylic Acid Ticlopidine Clopidogrel Prasugrel Thienopyridines Cilostazol Dipyridamole Novel Agents.

Presentation transcript:

PPIs reduces the antiplatelt effects of clopidogrel: According to a 2007 survey, clopidogrel is the sixth most commonly dispensed medication in the USA. To reduce the risk for gastrointestinal bleeding, clinicians often prescribe a concomitant proton-pump inhibitor (PPI) for high-risk patients. Recent evidence suggests that certain PPIs reduce the antiplatelet effects of clopidogrel. Clopidogrel, a prodrug, requires metabolism in the liver via cytochrome P450 (CYP) enzymes.

PPIs reduces the antiplatelt effects of clopidogrel: Proposed mechanism Once activated, clopidogrel blocks platelet aggregation by inhibiting adenosine diphosphate at the P2Y12 receptor. PPIs, such as omeprazole and its S-enantiomer esomeprazole (Nexium ® ), are thought to inhibit the CYP2C19 enzyme, thus negating the antithrombotic effects of clopidogrel. CYP2C19 also acts as the primary enzyme responsible for determining a patient’s pharmacodynamic response to clopidogrel.

PPIs reduces the antiplatelt effects of clopidogrel: Gilard and colleagues: Randomized, double-blind, placebo-controlled study. 145 patients undergoing PCI and receiving aspirin, 75 mg daily, and clopidogrel, 75 mg daily (after a 300-mg loading dose). 2 groups: The treatment group received omeprazole, 20 mg daily for 7 days, and the control group received placebo for 7 days. Assessment of the platelet reactivity index (PRI) was the primary endpoint. A PRI less than 50% indicated a favorable response to clopidogrel.

PPIs reduces the antiplatelt effects of clopidogrel: 145 patients undergoing PCI and receiving Aspirin, 75 mg daily, and clopidogrel, 75 mg daily (after a 300-mg loading dose). Pre-treatment: the PRI was 83.2% in the control group and 83.9% in the treatment group. Post-treatment: the PRI was 39.8% in the control group and 51.4% in the treatment group (P <.001). The long-term implications of this interaction are uncertain but may suggest reduced cardioprotective benefits of clopidogrel.